We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.29 | 0.66% | 43.99 | 44.33 | 43.685 | 43.93 | 12,104,157 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) Tuesday said a phase 3 study evaluating its cancer drug Opdivo plus low-dose Yervoy combined with chemotherapy met its primary endpoint of superior overall survival for the first-line treatment of advanced non-small cell lung cancer.
The New York biopharmaceutical company said the study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy versus chemotherapy alone.
Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer, accounting for up to 85% of diagnoses.
Bristol-Myers said it plans to complete a full evaluation of the study results, which it said build on the benefit the combination of Opdivo plus Yervoy has previously shown in other cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 22, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
